Advancement of Antibody-Drug conjugates in cancer treatment: A review
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | أطروحة |
| اللغة: | en_US |
| منشور في: |
Brac University
2022
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://hdl.handle.net/10361/17089 |
| id |
10361-17089 |
|---|---|
| record_format |
dspace |
| spelling |
10361-170892022-08-14T21:01:34Z Advancement of Antibody-Drug conjugates in cancer treatment: A review Sagar, Baejid Hossain Kabir, Dr. Eva Rahman Department of Pharmacy, Brac University Antibody-drug conjugates Cytotoxic payloads Monoclonal antibodies linkers Antibody-drug conjugates Antibody-toxin conjugates This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. Cataloged from PDF version of thesis report. Includes bibliographical references (pages 27-40). Antibody-drug conjugates (ADCs) are a rapidly growing class of biotherapeutic, targeted to selectively introduce cytotoxic agents into the cancer cell by means of monoclonal antibodies. USFDA has approved ten ADCs till date indicated for the treatment of breast cancer, urothelial cancer, myeloma, acute leukemia, and lymphoma. Besides, more than 80 ADCs are currently undergoing different phases of clinical trials. However, toxicity and non-specificity in treatment of solid tumors have led to challenges in the development of this novel and emerging class of anticancer treatment agents. Recent development in antibody, payload, and linker manufacturing technologies are helping to reduce the toxicity and define the future of ADCs. The current review is a compilation that reflects the recent advancements in the field of ADCs and covers the basic aspects of ADCs, emphasizing on the current development in ADCs, as well as future directions. Baejid Hossain Sagar B. Pharmacy 2022-08-14T06:44:17Z 2022-08-14T06:44:17Z 2022 2022-01 Thesis ID: 18146012 http://hdl.handle.net/10361/17089 en_US Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 40 Pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
en_US |
| topic |
Antibody-drug conjugates Cytotoxic payloads Monoclonal antibodies linkers Antibody-drug conjugates Antibody-toxin conjugates |
| spellingShingle |
Antibody-drug conjugates Cytotoxic payloads Monoclonal antibodies linkers Antibody-drug conjugates Antibody-toxin conjugates Sagar, Baejid Hossain Advancement of Antibody-Drug conjugates in cancer treatment: A review |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. |
| author2 |
Kabir, Dr. Eva Rahman |
| author_facet |
Kabir, Dr. Eva Rahman Sagar, Baejid Hossain |
| format |
Thesis |
| author |
Sagar, Baejid Hossain |
| author_sort |
Sagar, Baejid Hossain |
| title |
Advancement of Antibody-Drug conjugates in cancer treatment: A review |
| title_short |
Advancement of Antibody-Drug conjugates in cancer treatment: A review |
| title_full |
Advancement of Antibody-Drug conjugates in cancer treatment: A review |
| title_fullStr |
Advancement of Antibody-Drug conjugates in cancer treatment: A review |
| title_full_unstemmed |
Advancement of Antibody-Drug conjugates in cancer treatment: A review |
| title_sort |
advancement of antibody-drug conjugates in cancer treatment: a review |
| publisher |
Brac University |
| publishDate |
2022 |
| url |
http://hdl.handle.net/10361/17089 |
| work_keys_str_mv |
AT sagarbaejidhossain advancementofantibodydrugconjugatesincancertreatmentareview |
| _version_ |
1814308242285658112 |